Rodatristat ethyl (100 or 200 mg/kg; oral administration; once daily; for 28 days; male Sprague-Dawley rats) treatment decreases erum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduces pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats with monocrotaline (MCT)[1].
| Animal Model: | Male Sprague-Dawley rats (175-200 g)[1] |
| Dosage: | 100 mg/kg or 200 mg/kg |
| Administration: |
Oral administration; once daily; for 28 days |
| Result: | Decreased serum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduced pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats.
|
